Taken together, these findings are striking and show another facet of the cell evolution landscape [51], highlighting the possibility of cancer cells resisting targeted treatment to molecules such as HER2 or EGFR by acquiring oncogenic mutations in downstream pathways. This evidence concerns the gene EGFR and cancer.